1. Meningococcal vaccination: Cui bono?

   • Thomas D. Szucs

   Editorial 17 September 2012 Pages: 315 - 316

2. Future challenges for the economic evaluation of healthcare

   • John F. P. Bridges

   Commentary 17 September 2012 Pages: 317 - 321

3. Pharmacoeconomic analyses using discrete event simulation

   • J. Jaime Caro

   Current Opinion 17 September 2012 Pages: 323 - 332

   

4. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis

   • Mark A. Miller
   • Cathryn K. Shahab

   Leading Article 17 September 2012 Pages: 333 - 343

   

5. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease

   • Helen Doll
   • Marc Miravitlles

   Review Article 17 September 2012 Pages: 345 - 363

   

6. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

   • Claes-Göran Löfdahl
   • Åsa Ericsson
   • Emma Andreasson

   Original Research Article 17 September 2012 Pages: 365 - 375

   

7. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany

   • Peter K. Schädlich
   • Henning Zeidler
   • Eduard Huppertz

   Original Research Article 17 September 2012 Pages: 377 - 393

   

8. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany

   • Peter K. Schädlich
   • Henning Zeidler
   • Eduard Huppertz

   Original Research Article 17 September 2012 Pages: 395 - 420